VFA
ITCI

Virtus Fund Advisers’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

Virtus Fund Advisers’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		$335K Buy
+23,102
New +$357K ﹤0.01% 431
2014
Q3 		– Sell
-1,459
Closed -$25K – 1993
2014
Q2 		$25K Buy
+1,459
New +$24.1K ﹤0.01% 2308

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $1.06B AUM 52.03% 1-Year Est. Return
SC
Samlyn Capital New York $6.14B AUM 42.05% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Virtus Fund Advisers's ITCI Position: Q4 2017 in Review

Virtus Fund Advisers opened a new position in Intra-Cellular Therapies Inc. (ITCI) in Q4 2017: 23,102 shares worth $335K. The stake represents ﹤0.01% of the portfolio and ranks #431 among its holdings. This is a return to the name: Virtus Fund Advisers previously reported a position in ITCI as recently as Q2 2014.

Virtus Fund Advisers first reported a position in ITCI in Q2 2014 and has held it in 2 quarters since. 131 funds tracked by Wall St. Rank hold ITCI as of Q4 2017.

  • Virtus Fund Advisers held 23,102 shares of Intra-Cellular Therapies Inc. worth $335K as of Q4 2017.
  • Intra-Cellular Therapies Inc. was a new Virtus Fund Advisers position in Q4 2017.
  • Intra-Cellular Therapies Inc. made up ﹤0.01% of Virtus Fund Advisers's portfolio in Q4 2017, its #431 holding.
  • Virtus Fund Advisers first reported a position in Intra-Cellular Therapies Inc. in Q2 2014 and has held it in 2 quarters since.
  • 131 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q4 2017.

Based on Virtus Fund Advisers's 13F filing for Q4 2017, filed 9 Feb 2018.